National Foundation for the Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Clin Infect Dis. 2020 Dec 1;71(Suppl 3):S222-S231. doi: 10.1093/cid/ciaa1320.
Enteric fever can lead to prolonged hospital stays, clinical complications, and death. The Surveillance for Enteric Fever in Asia Project (SEAP), a prospective surveillance study, characterized the burden of enteric fever, including illness severity, in selected settings in Bangladesh, Nepal, and Pakistan. We assessed disease severity, including hospitalization, clinical complications, and death among SEAP participants.
We analyzed clinical and laboratory data from blood culture-confirmed enteric fever cases enrolled in SEAP hospitals and associated network laboratories from September 2016 to September 2019. We used hospitalization and duration of hospital stay as proxies for severity. We conducted a follow-up interview 6 weeks after enrollment to ascertain final outcomes.
Of the 8705 blood culture-confirmed enteric fever cases enrolled, we identified 6 deaths (case-fatality ratio, .07%; 95% CI, .01-.13%), 2 from Nepal, 4 from Pakistan, and none from Bangladesh. Overall, 1.7% (90/5205) of patients recruited from SEAP hospitals experienced a clinical complication (Bangladesh, 0.6% [18/3032]; Nepal, 2.3% [12/531]; Pakistan, 3.7% [60/1642]). The most identified complications were hepatitis (n = 36), septic shock (n = 22), and pulmonary complications/pneumonia (n = 13). Across countries, 32% (2804/8669) of patients with hospitalization data available were hospitalized (Bangladesh, 27% [1295/4868]; Nepal, 29% [455/1595]; Pakistan, 48% [1054/2206]), with a median hospital stay of 5 days (IQR, 3-7).
While defined clinical complications and deaths were uncommon at the SEAP sites, the high proportion of hospitalizations and prolonged hospital stays highlight illness severity and the need for enteric fever control measures, including the use of typhoid conjugate vaccines.
肠热病可导致住院时间延长、临床并发症和死亡。亚洲肠热病监测项目(SEAP)是一项前瞻性监测研究,对孟加拉国、尼泊尔和巴基斯坦选定地点的肠热病负担进行了特征描述,包括疾病严重程度。我们评估了 SEAP 参与者的疾病严重程度,包括住院、临床并发症和死亡。
我们分析了 2016 年 9 月至 2019 年 9 月期间在 SEAP 医院和相关网络实验室登记的血液培养确诊肠热病病例的临床和实验室数据。我们使用住院和住院时间作为严重程度的替代指标。我们在登记后 6 周进行了随访访谈,以确定最终结局。
在 8705 例血液培养确诊的肠热病病例中,我们确定了 6 例死亡(病死率,0.07%;95%CI,0.01-0.13%),2 例来自尼泊尔,4 例来自巴基斯坦,均无孟加拉国。总体而言,从 SEAP 医院招募的 5205 名患者中有 1.7%(90/5205)出现临床并发症(孟加拉国 0.6%[18/3032];尼泊尔 2.3%[12/531];巴基斯坦 3.7%[60/1642])。最常见的并发症是肝炎(n=36)、感染性休克(n=22)和肺部并发症/肺炎(n=13)。在各国中,有住院数据的 32%(2804/8669)患者住院(孟加拉国 27%[1295/4868];尼泊尔 29%[455/1595];巴基斯坦 48%[1054/2206]),中位住院时间为 5 天(IQR,3-7)。
虽然 SEAP 地点的明确临床并发症和死亡并不常见,但高比例的住院和延长的住院时间突出了疾病的严重程度,需要采取肠热病控制措施,包括使用伤寒结合疫苗。